Controversies in polio immunization

Indian Journal of Pediatrics

Volumn 70, Issue 7, 2003, Pages 567-571

  Thacker, Naveen ^a,c   Shendurnikar, Niranjan ^b  

^a Deep Children Hospital   (India)

^b Baroda Medical College   (India)

^c NONE   (India)

Author keywords

Polio eradication; Polio vaccine; VAPP

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

ACTIVE IMMUNIZATION; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; DRUG MECHANISM; HUMAN; PARALYSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PREVENTIVE HEALTH SERVICE; SIDE EFFECT; VACCINATION; VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS;

EID: 0043237490     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02723160     Document Type: Conference Paper

References (39)

1. Soto NE, Lutwick L. Polio virus:what goes around, comes around. Infect Dis Clin North Amer 1999; 13: 265-278.
2. Hull HF, Ward NA, Hull BP, Milstein JB, de Quadros Ciro. Paralytic poliomyelitis:seasoned strategies,disappearing disease. Lancet 1994; 343: 1331-1337.
3. Banerjee K, Sahu S, Bandyopadhyay S. Polio eradication in India. How far are we from reaching the goal? Indian J Pediatr 2001; 68: S6-S14.
4. Patriacia PA, Wright PF, John TJ. Factors affecting the immunogenecity of oral polio vaccine in developing countries: review. Rev Infect Dis 1991; 13: 926-939.
5. World Health Organization Collaborative Group on oral polio vaccine. Factors affecting the immunogenecity of oral polio vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995; 171: 1096-1006.
6. Mas Lago P, Bravo JR, Andrus JK et al. Lessons from Cuba: mass campaign administration of trivalent oral polio vaccine and sero prevelance of polio virus neutralizing antibodies. Bull WHO1994; 72: 221-225.
7. Chopra K, Kundu S, Chowdhary DS. Antibody response of infants in tropics to five doses of oral polio vaccine. J Trop Pediatr 1989; 35: 19-23.
8. Murdin AD, Barreto L, Plotkin S. Inactivated poliovirus vaccine; past and present experience. Vaccine 1996; 14: 735-746.
9. Posey DL, Linkins RW, Couto Oliveria MJ, Monteiro D, Patriarca PA. The effect of diarrhea on oral polio vaccine failure in Brazil. J Infect Dis 1997; 175: S258-S263.
10. Reichler MR, Kharabsheh S, Rhodes P et al. Increased immunogenecity of oral polio vaccine administered in mass vaccination campaigns compared with routine vaccination program in Jordon. J Infect Dis 1997; 175: S 198-S 204.
11. John TJ. Can we eradicate poliomyelitis? In Sachdev HPS, Choudhury P, eds. Frontiers in Pediatrics. Publ Jaypee, New Delhi. 1996; 76-89.
12. Bateman DE, Erlington G, Kennedy P et al. Vaccine related poliomyelitis in non immunized relatives and household contacts. Br Med J 1987; 294: 170-171.
13. Gross TP, Khurana RK, Higgins T et al. Vaccine associated poliomyelitis in a house hold contact receiving long term steroid therapy. Amer J Med 1987; 83: 797-800.
14. Melnick JL. Advantages and disadvantages of killed and live poliomyelitis vaccine. Bull WHO 1978; 56: 21-38.
15. CDC. Manual of Poliomyelitis 1999; 81-99.
16. Centers for Disease Control and Prevention. Paralytic Poliomyelitis-United States, 1980-1994. MMWR Morb Mortal Wkly Rep 1997; 46: 79-83.
17. Andrus JK, Strebel PM, de Quadros Ca, Olive JM. Risk of vaccine associated paralytic poliomyelitis in Latin America, 1989-91. Bull WHO 1995; 73: 33-40.
18. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and wales, 1985-91. Brit Med J 1992; 305: 79-82.
19. Strebel PM, Sutter RW, Cochi SL et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus associated disease. Clin Infect Dis 1992; 14: 568-579.
20. Kohler KA, Banerjee K, Hlady WG, Andrus JK, Sutter RW. Vaccine associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull WHO 2002; 80: 210-216.
21. Sutter RW, Prevots R, Cochi SL. Polio virus vaccines: progress towards global poliomyelitis eradication and changing routine immunization recommendations in United States. Pediatr Clin North Amer 2000; 47: 287-309.
22. Mcbean Am, Thomas ML, Albercht P et al. The Field Staff and Coordinating Committee; Serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Amer J Epidemiol 1988; 128: 615-628.
23. Modlin JF, Halsey NA, Thomas MA et al. The Baltimore Area Polio Vaccine Study Group; humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine:live attenuated oral polio virus vaccine immunization schedule. J Infect Dis 1997; 175: S228-S234.
24. Halsey NA, Blatter M, Bader G et al. Inactivated polio virus vaccine alone or sequential inactivated and oral polio virus vaccine in two, four and six month old infants with combination Hib/hepatitis B vaccine. Pediatr Infect Dis J 1997; 16: 675-679.
25. Grenier B, Hamza B, Biron G et al. Sero immunity following vaccination in infants by an inactivated poliovirus vaccine prepared on vero cells. Rev Infect Dis 1984; 6(S2)S345-S347.
26. Faden H, Duffy L, Sun M Shuff C. Long-term immunity to polio virus in children immunized with live attenuated and enhanced potency inactivated trivalent poliovirus vaccines. J Infect Dis 1993; 168: 452-454.
27. WHO Collaborative Study Group on Oral and Inactivated Poliovirus vaccines;Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia,Oman and Thialand. J Infect Dis 1997; 175(Supp 1) S215-S227.
28. Faden FH, Modlin JF, Thomas ML et al. Comparative evaluation of immunization with live attenuated and enhanced potency inactivated trivalent polio virus vaccines in childhood:systemic and immune responses. J Infect Dis 1990; 162: 1291-1297.
29. Halperin SA, Davies D, Barreto L et al. Safety and immunogenecity of two inactivated poliovirus vaccines in combination with acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen to 19-month-old infants. J Pediatr 1997; 130: 525-531.
30. Vidor E, Meschievitz C,Plotkin S. Fifteen years experience with vero produced enhanced potency inactivated polio virus vaccine. Pediatr Infect Dis J 1997; 16: 312-322.
31. Bernier RH. Improved inactivated poliovirus vaccine:an update. Pediatr Infect Dis J 1986; 5: 289-292.
32. Robertson SE, Drucker JA, Fabre-Teste B et al. Clinical efficacy of a new enhanced potency inactivated poliovirus vaccine. Lancet 1998; 352: 897-899.
33. Vidor E, Caudrelier P, Plotkin S. The place of DTP/eIPV vaccine in routine pediatric vaccination. Rev Med Virol 1994; 4: 261-277.
34. du Chatelet IP, Merchant AT, Fisher-Hoch S et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003; 21: 1710-8.
35. Lasch EE, Abde Y, Abdulla K et al. Successful results of a program combining live and inactivated poliovirus vaccine to control poliomyelitis in Gaza. Rev Infect Dis 1984; 6(S2): S467-S470.
36. Wood DJ, Sutter RW, Dowdle WR. Stopping poliovirus vaccination after eradication:issues and challenges. Bull WHO 2000; 78: 347-357.
37. Adenyi-Jones SC, Faden H, Ferdon MS, Kwong MS, Ogra PL. systemic and local immune responses to enhanced potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992; 120: 686-689.
38. Onorato IM, Modlin JF, Mcbean AM et al. Mucosal immunity induced by enhanced potency inactivated and oral polio vaccines. J Infect Dis 1991; 163: 1-6.
39. Faden H. Poliovirus vaccination: a triology. J Infect Dis 1993; 163: 25-28.